Drug Delivery Devices – Market Insights – Europe

The European drug delivery device market will see modest growth through 2027. Although the increasing availability of biosimilars will negatively impact ASPs, the greater affordability of lower-cost generic drug delivery devices will support rising overall sales volumes, which will be further supported by expanding patient populations.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for drug delivery devices in Europe across a 10-year period.

The adoption of drug delivery devices varies widely across Europe, based on physician preferences as well as cultural and economic factors.

Why do physicians and patients in the countries covered prefer certain devices, and how will this impact drug delivery device adoption over the forecast period?

How will device preferences change over the forecast period?

Several new drug delivery technologies are in development, including microneedle transdermal patches and subcutaneous implants.

What kinds of conditions are these new devices targeting?

Which products hold the greatest promise for successful adoption after launch?

How will the launch of new products influence ASPs and competitor dynamics?

What considerations must be taken into account for new competitors intending to enter the market?

Innovations and product improvements will strongly influence growth in the injection device market.

How will innovative devices, such as needle-free injection systems and smart devices, contribute to the growth of the injection device market?

How will adoption of emerging alternative technologies, such as insulin pumps and closed-loop systems, affect injection device sales?